CA2325351C - Non-stochastic generation of genetic vaccines and enzymes - Google Patents
Non-stochastic generation of genetic vaccines and enzymes Download PDFInfo
- Publication number
- CA2325351C CA2325351C CA002325351A CA2325351A CA2325351C CA 2325351 C CA2325351 C CA 2325351C CA 002325351 A CA002325351 A CA 002325351A CA 2325351 A CA2325351 A CA 2325351A CA 2325351 C CA2325351 C CA 2325351C
- Authority
- CA
- Canada
- Prior art keywords
- cassette
- degenerate
- mononucleotide
- polynucleotide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 186
- 230000002068 genetic effect Effects 0.000 title claims abstract description 183
- 102000004190 Enzymes Human genes 0.000 title abstract description 44
- 108090000790 Enzymes Proteins 0.000 title abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 456
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 349
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 349
- 239000002157 polynucleotide Substances 0.000 claims abstract description 349
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 239
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 226
- 229920001184 polypeptide Polymers 0.000 claims abstract description 210
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 183
- 239000013598 vector Substances 0.000 claims abstract description 168
- 108091007433 antigens Proteins 0.000 claims abstract description 141
- 239000000427 antigen Substances 0.000 claims abstract description 140
- 102000036639 antigens Human genes 0.000 claims abstract description 138
- 230000028993 immune response Effects 0.000 claims abstract description 110
- 238000002703 mutagenesis Methods 0.000 claims abstract description 67
- 231100000350 mutagenesis Toxicity 0.000 claims abstract description 67
- 230000014509 gene expression Effects 0.000 claims abstract description 55
- 230000001965 increasing effect Effects 0.000 claims abstract description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 281
- 102000039446 nucleic acids Human genes 0.000 claims description 264
- 108020004707 nucleic acids Proteins 0.000 claims description 264
- 210000004027 cell Anatomy 0.000 claims description 227
- 238000012216 screening Methods 0.000 claims description 99
- 230000001976 improved effect Effects 0.000 claims description 78
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 60
- 230000027455 binding Effects 0.000 claims description 57
- 108090000695 Cytokines Proteins 0.000 claims description 56
- 102000004127 Cytokines Human genes 0.000 claims description 55
- 238000001727 in vivo Methods 0.000 claims description 54
- 125000003729 nucleotide group Chemical group 0.000 claims description 54
- 238000000338 in vitro Methods 0.000 claims description 53
- 108091034117 Oligonucleotide Proteins 0.000 claims description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 102000005962 receptors Human genes 0.000 claims description 40
- 108020003175 receptors Proteins 0.000 claims description 40
- 241000282414 Homo sapiens Species 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 31
- 230000008569 process Effects 0.000 claims description 30
- 238000006467 substitution reaction Methods 0.000 claims description 30
- 108020004705 Codon Proteins 0.000 claims description 28
- 230000000897 modulatory effect Effects 0.000 claims description 27
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 25
- 230000002163 immunogen Effects 0.000 claims description 23
- 230000005847 immunogenicity Effects 0.000 claims description 23
- 241001515965 unidentified phage Species 0.000 claims description 20
- 230000001939 inductive effect Effects 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 230000003321 amplification Effects 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 18
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 18
- 230000002519 immonomodulatory effect Effects 0.000 claims description 17
- 108091026890 Coding region Proteins 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000003259 recombinant expression Methods 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 244000045947 parasite Species 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 9
- 108010065805 Interleukin-12 Proteins 0.000 claims description 9
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- -1 IL-14 Proteins 0.000 claims description 7
- 108090000978 Interleukin-4 Proteins 0.000 claims description 7
- 102000004388 Interleukin-4 Human genes 0.000 claims description 7
- 102000013462 Interleukin-12 Human genes 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 108010057085 cytokine receptors Proteins 0.000 claims description 6
- 102000003675 cytokine receptors Human genes 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 101150013553 CD40 gene Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 102000003816 Interleukin-13 Human genes 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 102000000743 Interleukin-5 Human genes 0.000 claims description 4
- 230000006052 T cell proliferation Effects 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 239000000430 cytokine receptor antagonist Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 230000008488 polyadenylation Effects 0.000 claims description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 2
- 229940117681 interleukin-12 Drugs 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 9
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims 4
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 108090000237 interleukin-24 Proteins 0.000 claims 2
- 102000003898 interleukin-24 Human genes 0.000 claims 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 241000209510 Liliopsida Species 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 241001233957 eudicotyledons Species 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 claims 1
- 102000014452 scavenger receptors Human genes 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 230000000704 physical effect Effects 0.000 abstract description 2
- 230000000079 pharmacotherapeutic effect Effects 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 81
- 235000018102 proteins Nutrition 0.000 description 78
- 108020004414 DNA Proteins 0.000 description 75
- 235000001014 amino acid Nutrition 0.000 description 61
- 230000035772 mutation Effects 0.000 description 60
- 238000009739 binding Methods 0.000 description 57
- 229940024606 amino acid Drugs 0.000 description 52
- 241000894007 species Species 0.000 description 43
- 239000000047 product Substances 0.000 description 42
- 229940088598 enzyme Drugs 0.000 description 41
- 230000015572 biosynthetic process Effects 0.000 description 36
- 238000003786 synthesis reaction Methods 0.000 description 33
- 230000001717 pathogenic effect Effects 0.000 description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 description 28
- 210000000612 antigen-presenting cell Anatomy 0.000 description 27
- 244000052769 pathogen Species 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 239000000758 substrate Substances 0.000 description 22
- 238000013459 approach Methods 0.000 description 20
- 230000000670 limiting effect Effects 0.000 description 20
- 230000000890 antigenic effect Effects 0.000 description 19
- 230000008878 coupling Effects 0.000 description 19
- 238000010168 coupling process Methods 0.000 description 19
- 238000005859 coupling reaction Methods 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 19
- 230000006872 improvement Effects 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 230000003505 mutagenic effect Effects 0.000 description 18
- 238000004422 calculation algorithm Methods 0.000 description 17
- 231100000219 mutagenic Toxicity 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 150000007513 acids Chemical class 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 238000005457 optimization Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 230000006798 recombination Effects 0.000 description 13
- 238000005215 recombination Methods 0.000 description 13
- 230000009870 specific binding Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 238000002741 site-directed mutagenesis Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 238000001994 activation Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 201000004792 malaria Diseases 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 229940124856 vaccine component Drugs 0.000 description 11
- 241000223960 Plasmodium falciparum Species 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 108020004638 Circular DNA Proteins 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 101710198693 Invasin Proteins 0.000 description 9
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 108010011619 6-Phytase Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 238000011239 genetic vaccination Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 229940085127 phytase Drugs 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000009897 systematic effect Effects 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000003471 mutagenic agent Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 101000723939 Mus musculus Transcription factor HIVEP3 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 108010045374 CD36 Antigens Proteins 0.000 description 4
- 102000053028 CD36 Antigens Human genes 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 230000017274 T cell anergy Effects 0.000 description 4
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000012219 cassette mutagenesis Methods 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000010502 episomal replication Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000009919 sequestration Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 241000282708 Aotus <primate> Species 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 101710160107 Outer membrane protein A Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 102000002938 Thrombospondin Human genes 0.000 description 3
- 108060008245 Thrombospondin Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001371 alpha-amino acids Chemical class 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000033607 mismatch repair Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 102000044158 nucleic acid binding protein Human genes 0.000 description 3
- 108700020942 nucleic acid binding protein Proteins 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000003334 potential effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 2
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 241000224024 Plasmodium chabaudi Species 0.000 description 2
- 241000223801 Plasmodium knowlesi Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000027645 antigenic variation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000002729 polyribosome Anatomy 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001915 proofreading effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000014639 sexual reproduction Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 description 1
- 101710133850 Hypermethylated in cancer 1 protein Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 108010088113 Plasmodium falciparum erythrocyte membrane protein 1 Proteins 0.000 description 1
- 241000223819 Plasmodium fragile Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 102100028082 Tapasin Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229940076005 apoptosis modulator Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003126 m-cell Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 230000034778 micropinocytosis Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 108010088142 pfalhesin Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 101150056906 recJ gene Proteins 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 101150072534 sbcB gene Proteins 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000003373 small molecule array Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 101150115617 umuC gene Proteins 0.000 description 1
- 101150046028 umuD gene Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 101150100239 vsr gene Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
- C12Y301/11002—Exodeoxyribonuclease III (3.1.11.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ecology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2492661A CA2492661C (en) | 1999-02-04 | 2000-02-04 | Non-stochastic generation of genetic vaccines and enzymes |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/246,178 US6171820B1 (en) | 1995-12-07 | 1999-02-04 | Saturation mutagenesis in directed evolution |
| US09/246,178 | 1999-02-04 | ||
| PCT/US2000/003086 WO2000046344A2 (en) | 1999-02-04 | 2000-02-04 | Non-stochastic generation of genetic vaccines and enzymes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2492661A Division CA2492661C (en) | 1999-02-04 | 2000-02-04 | Non-stochastic generation of genetic vaccines and enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2325351A1 CA2325351A1 (en) | 2000-08-10 |
| CA2325351C true CA2325351C (en) | 2005-02-01 |
Family
ID=22929614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002325351A Expired - Fee Related CA2325351C (en) | 1999-02-04 | 2000-02-04 | Non-stochastic generation of genetic vaccines and enzymes |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6171820B1 (enExample) |
| JP (2) | JP2003524392A (enExample) |
| AU (1) | AU3483900A (enExample) |
| CA (1) | CA2325351C (enExample) |
| WO (1) | WO2000046344A2 (enExample) |
Families Citing this family (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6939689B2 (en) | 1995-12-07 | 2005-09-06 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6740506B2 (en) * | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US6764835B2 (en) * | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US20030219752A1 (en) * | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| EP2261373A3 (en) | 1997-01-17 | 2011-12-14 | Codexis Mayflower Holdings, LLC | Evolution of whole cells and organisms by recursive sequence recombination |
| US7148054B2 (en) * | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6159688A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
| WO1999021977A1 (en) * | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
| WO1999029902A1 (en) | 1997-12-08 | 1999-06-17 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| CA2325567A1 (en) | 1998-05-01 | 1999-11-11 | Maxygen, Inc. | Optimization of pest resistance genes using dna shuffling |
| US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| US6951719B1 (en) | 1999-08-11 | 2005-10-04 | Proteus S.A. | Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained |
| US20030104417A1 (en) * | 1998-08-12 | 2003-06-05 | Proteus S.A. | Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides |
| US6991922B2 (en) * | 1998-08-12 | 2006-01-31 | Proteus S.A. | Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation |
| US20030092023A1 (en) * | 1998-08-12 | 2003-05-15 | Daniel Dupret | Method of shuffling polynucleotides using templates |
| ATE439437T1 (de) * | 1999-01-05 | 2009-08-15 | Univ Boston | Verbessertes klonierungsverfahren |
| US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| EP1151409A1 (en) * | 1999-01-18 | 2001-11-07 | Maxygen, Inc. | Methods of populating data stuctures for use in evolutionary simulations |
| US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US20090130718A1 (en) * | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
| JP3399518B2 (ja) * | 1999-03-03 | 2003-04-21 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 半導体構造およびその製造方法 |
| US6365377B1 (en) | 1999-03-05 | 2002-04-02 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
| US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| EP1230269A2 (en) | 1999-11-03 | 2002-08-14 | Maxygen, Inc. | Antibody diversity generation |
| US7115712B1 (en) * | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
| IL150291A0 (en) * | 2000-01-11 | 2002-12-01 | Maxygen Inc | Integrated systems and methods for diversity generation and screening |
| AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
| US20010049104A1 (en) * | 2000-03-24 | 2001-12-06 | Stemmer Willem P.C. | Methods for modulating cellular and organismal phenotypes |
| US6479262B1 (en) | 2000-05-16 | 2002-11-12 | Hercules, Incorporated | Solid phase enzymatic assembly of polynucleotides |
| AU2001268716A1 (en) * | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel chimeric promoters |
| AU2001272978A1 (en) * | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel co-stimulatory molecules |
| WO2002004629A2 (en) * | 2000-07-07 | 2002-01-17 | Maxygen, Inc. | Molecular breeding of transposable elements |
| US6858422B2 (en) * | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
| AU2001277014A1 (en) * | 2000-07-21 | 2002-02-05 | Trustees Of Boston University | Modular vector systems |
| US7435562B2 (en) * | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| CN1468313A (zh) * | 2000-08-24 | 2004-01-14 | �����ɷ� | 新颖的构建物及其在代谢途径工程中的用途 |
| JP2002083691A (ja) * | 2000-09-06 | 2002-03-22 | Sharp Corp | アクティブマトリックス駆動型有機ｌｅｄ表示装置及びその製造方法 |
| US20040006778A1 (en) * | 2002-02-15 | 2004-01-08 | Diversa Corporation | Chimeric cannulae proteins, nucleic acids encoding them and methods for making and using them |
| US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
| CA2436214C (en) * | 2001-02-02 | 2012-12-04 | Large Scale Biology Corporation | A method of increasing complementarity in a heteroduplex polynucleotide |
| US20030036854A1 (en) * | 2001-02-06 | 2003-02-20 | The Penn State Research Foundation | Apparatus and method for designing proteins and protein libraries |
| EP1277835A1 (en) * | 2001-07-19 | 2003-01-22 | Libragen | Methods of creating genetic diversity |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
| CA2462930C (en) | 2001-10-10 | 2012-07-10 | Shawn De Frees | Remodeling and glycoconjugation of peptides |
| JP2005511045A (ja) * | 2001-12-03 | 2005-04-28 | ディヴァーサ コーポレイション | 染色体飽和変異誘発 |
| TWI262083B (en) * | 2001-12-28 | 2006-09-21 | Syngenta Participations Ag | Microbially-expressed thermotolerant phytase for animal feed |
| US20040009498A1 (en) * | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
| WO2003068948A1 (en) | 2002-02-13 | 2003-08-21 | Dow Global Technologies Inc. | Over-expression of extremozyme genes in pseudomonads and closely related bacteria |
| US20030224404A1 (en) * | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
| AU2003217716A1 (en) * | 2002-02-25 | 2003-09-09 | Cabot Corporation | Custom ligand design for biomolecular filtration and purification for bioseperation |
| AU2003216507A1 (en) | 2002-03-01 | 2003-09-16 | Maxygen, Inc. | Methods, systems, and software for identifying functional bio-molecules |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20030199068A1 (en) * | 2002-03-05 | 2003-10-23 | Bott Richard R. | High throughput mutagenesis screening method |
| US20030171543A1 (en) * | 2002-03-05 | 2003-09-11 | Bott Richard R. | High throughput mutagenesis screening method |
| AU2003213846A1 (en) | 2002-03-09 | 2003-09-29 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
| EA010903B1 (ru) | 2002-04-19 | 2008-12-30 | Дайверса Корпорейшн | Фосфолипазы, нуклеиновые кислоты, кодирующие их, и способы их получения и применения |
| US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
| DK1504098T4 (da) * | 2002-05-17 | 2011-05-23 | Alligator Bioscience Ab | Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion |
| AU2003253992A1 (en) * | 2002-07-18 | 2004-02-09 | Robert P. Bennett | Viral vectors containing recombination sites |
| EP1546349A1 (en) * | 2002-08-02 | 2005-06-29 | Aromagen Corporation | Methods for making (-) -menthol and oxygenated menthane compounds |
| MXPA05001287A (es) | 2002-08-06 | 2005-08-03 | Verdia Llc | Variantes de amino oxidasa ap1. |
| ATE466085T1 (de) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| EP3321282A1 (en) | 2002-09-27 | 2018-05-16 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| MX295545B (es) | 2003-03-07 | 2012-02-03 | Diversa Corp | Hidrolasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas. |
| US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| JP2007500514A (ja) | 2003-04-29 | 2007-01-18 | パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド | 新規なグリホセートｎ−アセチルトランスフェラーゼ（ｇａｔ）遺伝子 |
| US20050095615A1 (en) * | 2003-06-26 | 2005-05-05 | Welch Peter J. | Methods and compositions for detecting promoter activity and expressing fusion proteins |
| AU2003283943A1 (en) * | 2003-11-20 | 2005-06-08 | Agency For Science Technology And Research | Method |
| ATE469984T1 (de) | 2003-12-01 | 2010-06-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
| US7204950B2 (en) * | 2003-12-19 | 2007-04-17 | Pepsico, Inc. | Dispensing package |
| AR048744A1 (es) | 2004-02-25 | 2006-05-24 | Pionner Hi Bred Internat Inc | Polipeptidos cristalinos y polinucleotidos de bacillus thuringiensis y composiciones con los mismos |
| CN101023181A (zh) | 2004-05-21 | 2007-08-22 | 加利福尼亚大学董事会 | 提高类异戊二烯化合物的产生的方法 |
| CA2735315A1 (en) | 2004-06-09 | 2005-12-29 | Pioneer Hi-Bred International, Inc. | Plastid transit peptides |
| US8216804B2 (en) | 2004-10-27 | 2012-07-10 | The Scripps Research Institute | Orthogonal translation components for the in vivo incorporation of unnatural amino acids |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| JP2008519602A (ja) * | 2004-11-11 | 2008-06-12 | モジュラー ジェネティクス， インコーポレイテッド | 多様性を生じるためのラダーアセンブリおよびシステム |
| CA2614769A1 (en) | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| CN102943085A (zh) | 2005-03-15 | 2013-02-27 | 维莱尼姆公司 | 纤维素酶、编码它们的核酸及其制备和应用的方法 |
| US20070184472A1 (en) * | 2005-06-08 | 2007-08-09 | Toagosei Co., Ltd | Method of purifying environmental dna and method of efficiently screening for protein-encoding gene from environmental dna |
| RU2518295C2 (ru) | 2005-06-21 | 2014-06-10 | Ксома Текнолоджи Лтд. | IL-1бета-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ФРАГМЕНТЫ |
| GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| EP2216403A3 (en) | 2006-02-02 | 2010-11-24 | Verenium Corporation | Esterases and related nucleic acids and methods |
| NZ595497A (en) | 2006-02-10 | 2013-09-27 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
| EP2548954A1 (en) | 2006-02-14 | 2013-01-23 | Verenium Corporation | Xylanases, nucleic acids encoding them and methods for making and using them |
| EP1999256B1 (en) | 2006-03-07 | 2012-03-07 | Verenium Corporation | Aldolases, nucleic acids encoding them and methods for making and using them |
| AU2007223913B2 (en) | 2006-03-07 | 2013-06-13 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
| US20080014205A1 (en) | 2006-05-15 | 2008-01-17 | Lawrence Horowitz | Neutralizing Antibodies to Influenza Viruses |
| US20070294785A1 (en) * | 2006-06-13 | 2007-12-20 | Athenix Corporation | Methods for generating genetic diversity by permutational mutagenesis |
| MX369001B (es) | 2006-08-04 | 2019-10-24 | Basf Enzymes Llc | Glucanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas. |
| PL2057274T3 (pl) | 2006-09-21 | 2014-05-30 | Dsm Ip Assets Bv | Fosfolipazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i stosowania |
| EP2617823B1 (en) | 2006-09-21 | 2015-07-01 | BASF Enzymes LLC | Phytases, nucleic acids encoding them and methods for making and using them |
| KR101378302B1 (ko) | 2006-12-20 | 2014-03-28 | 엠엠알글로벌, 인코포레이티드 | 항체 및 이들의 제조 및 사용 방법 |
| ES2575912T3 (es) | 2006-12-21 | 2016-07-04 | Basf Enzymes Llc | Amilasas y glucoamilasas, ácidos nucleicos que las codifican y métodos para formarlas y utilizarlas |
| WO2008095033A2 (en) | 2007-01-30 | 2008-08-07 | Verenium Corporation | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
| CN103476425B (zh) | 2007-03-30 | 2015-07-15 | 纽约州州立大学研究基金会 | 用于疫苗的减毒病毒 |
| BRPI0815046A2 (pt) | 2007-07-31 | 2014-10-14 | Verenium Corp | Personalização de montagem combinatória de múltiplos locais |
| NZ584967A (en) | 2007-10-03 | 2012-08-31 | Verenium Corp | Xylanases, nucleic acids encoding them and methods for making and using them |
| EP2219469B1 (en) | 2007-12-03 | 2017-08-30 | Syngenta Participations AG | Engineering enzymatically susceptible proteins |
| US9102711B2 (en) * | 2007-12-31 | 2015-08-11 | Xoma Technology Ltd. | Methods and materials for targeted mutagenesis |
| PL2238242T3 (pl) | 2008-01-03 | 2015-06-30 | Basf Enzymes Llc | Transferazy i oksydoreduktazy, kwasy nukleinowe kodujące je oraz sposoby ich wytwarzania i zastosowania |
| US8541220B2 (en) | 2008-01-03 | 2013-09-24 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
| JP2011518115A (ja) * | 2008-01-28 | 2011-06-23 | タップイミューン インコーポレイテッド | 免疫応答を増強するためのタパシン増加 |
| EP2698380A1 (en) | 2008-03-28 | 2014-02-19 | Sea Lane Biotechnologies, LLC | Neutralizing molecules to viral antigens |
| JP5718221B2 (ja) * | 2008-05-30 | 2015-05-13 | マサチューセッツ インスティテュート オブ テクノロジー | 細胞の空間的分離およびスクリーニングのための組成物および方法 |
| US20090312196A1 (en) * | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| US8383346B2 (en) * | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| PE20110942A1 (es) * | 2008-12-02 | 2011-12-30 | Consejo Nac Invest Cient Tec | Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos |
| AU2010247086A1 (en) | 2009-05-12 | 2011-12-01 | Council Of Scientific & Industrial Research | LipA and its variant useful for biofuel production |
| BRPI1011160A8 (pt) | 2009-05-21 | 2018-01-02 | Verenium Corp | Fitases, preparação de proteína que as compreende, e seus usos |
| BR122015012748A2 (pt) | 2009-07-17 | 2020-01-07 | Bioatla, Llc | Métodos de evolução, identificação e produção de uma proteína |
| UA109884C2 (uk) | 2009-10-16 | 2015-10-26 | Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування | |
| UA111708C2 (uk) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | Спосіб рафінування олії |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| ES2966088T3 (es) | 2010-07-16 | 2024-04-18 | Bioatla Inc | Nuevos métodos de evolución de proteínas |
| CA2805937A1 (en) | 2010-08-13 | 2012-02-16 | Pioneer Hi-Bred International, Inc. | Chimeric promoters and methods of use |
| US9234216B2 (en) | 2010-10-06 | 2016-01-12 | Bp Corporation North America Inc. | Variant CBH I polypeptides |
| US20140199682A1 (en) | 2010-11-17 | 2014-07-17 | Sea Lane Biotechnologies, Llc | Influenza neutralizing agents |
| US20140182011A1 (en) | 2011-11-03 | 2014-06-26 | The University Of Hong Kong | Methods Using Acyl-Coenzyme A-Binding Proteins to Enchance Drought Tolerance in Genetically Modified Plants |
| CN104540939A (zh) | 2012-03-16 | 2015-04-22 | Bp北美公司 | 具有内切葡聚糖酶活性的多肽 |
| CA2872096A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
| US9969813B2 (en) | 2012-05-10 | 2018-05-15 | Bioatla, Llc | Multi-specific monoclonal antibodies |
| PT2885406T (pt) | 2012-08-16 | 2018-11-16 | Bangladesh Jute Res Institute | Enzimas degradantes de celulose e/ou hemiceluloses de macrophomina phaseolina e utilizações das mesmas |
| ES2674922T3 (es) | 2012-08-16 | 2018-07-05 | Bangladesh Jute Research Institute | Enzimas degradantes de pectina a partir de macrophomina phaseolina y usos de las mismas |
| US10253325B2 (en) | 2012-12-19 | 2019-04-09 | Boston Medical Center Corporation | Methods for elevating fat/oil content in plants |
| AU2014212430B2 (en) * | 2013-01-31 | 2019-06-20 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules with interacting components |
| GB201308828D0 (en) | 2013-03-12 | 2013-07-03 | Verenium Corp | Phytase |
| EP2970935A1 (en) | 2013-03-14 | 2016-01-20 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
| GB201308843D0 (en) | 2013-03-14 | 2013-07-03 | Verenium Corp | Phytase formulation |
| US20140287419A1 (en) | 2013-03-14 | 2014-09-25 | Arzeda Corp. | Compositions Having Dicamba Decarboxylase Activity and Methods of Use |
| AR095173A1 (es) | 2013-07-25 | 2015-09-30 | Basf Enzymes Llc | Fitasa |
| CA2935577C (en) | 2014-01-07 | 2023-04-04 | Bioatla, Llc | Proteins targeting orthologs |
| WO2017062343A1 (en) | 2015-10-06 | 2017-04-13 | Pierce Biotechnology, Inc. | Devices and methods for producing nucleic acids and proteins |
| US11291221B2 (en) | 2015-10-30 | 2022-04-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
| AU2017386682A1 (en) | 2016-12-28 | 2019-07-25 | Invvax, Inc. | Influenza vaccines |
| US11542487B2 (en) | 2017-10-25 | 2023-01-03 | Basf Se | Beta-amylase enzymes |
| WO2019126211A1 (en) * | 2017-12-20 | 2019-06-27 | Basf Se | Gene site saturation mutagenesis (gssm) method |
| CN112368375A (zh) | 2018-04-26 | 2021-02-12 | 巴斯夫欧洲公司 | 脂肪酶 |
| EP3788145A1 (en) | 2018-05-03 | 2021-03-10 | Basf Se | Amylase enzymes |
| US12351841B2 (en) | 2018-05-29 | 2025-07-08 | Basf Se | Amylase enzymes |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| WO2020049159A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
| AU2019334671A1 (en) | 2018-09-07 | 2021-03-25 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of PUFA in plants |
| WO2020049155A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
| EP3938504A1 (en) | 2019-03-11 | 2022-01-19 | Basf Se | Amylases and methods for making and using them |
| DK3958890T3 (da) | 2019-04-23 | 2025-02-17 | Basf Se | Beta-amylasevarianter |
| KR20220119408A (ko) | 2019-12-20 | 2022-08-29 | 바스프 에스이 | 터펜의 독성 감소 및 미생물에서 생산 잠재성 증가 |
| EP4162061A1 (en) | 2020-06-04 | 2023-04-12 | Isobionics B.V. | Synthetic santalene synthases |
| EP4015626A1 (en) | 2020-12-18 | 2022-06-22 | Isobionics B.V. | Enzymes and methods for fermentative production of monoterpene esters |
| JP2024528957A (ja) | 2021-08-02 | 2024-08-01 | ビーエーエスエフ ソシエタス・ヨーロピア | イオニリデンエタンシンターゼによる新規な芳香化合物の生成 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959312A (en) | 1985-05-31 | 1990-09-25 | The University Of Tennessee Research Corporation | Full spectrum mutagenesis |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE69332908T2 (de) | 1992-11-24 | 2003-12-24 | G.D. Searle & Co., Chicago | Interleukin-3 (il-3)-polypeptide mith mehreren mutationen |
| WO1995010603A1 (en) * | 1993-10-08 | 1995-04-20 | Novo Nordisk A/S | Amylase variants |
| US6187579B1 (en) | 1993-10-28 | 2001-02-13 | Carlsberg A/S | Customized proteases |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US5389537A (en) | 1994-01-21 | 1995-02-14 | Wisconsin Alumni Research Foundation | Nuclease having altered specificity |
| AU3330895A (en) | 1994-08-18 | 1996-03-14 | Cytogen Corporation | Peptide librairies as a source of syngenes |
| US5885577A (en) | 1994-09-21 | 1999-03-23 | Cytogen Corporation | Antigen binding peptides (abtides) from peptide libraries |
| ATE217344T1 (de) | 1994-09-21 | 2002-05-15 | Cytogen Corp | Antigen bindende peptide (abtides) aus peptidbibliotheken |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| WO1998048024A1 (en) | 1997-04-18 | 1998-10-29 | Biogen, Inc. | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
| AU7171098A (en) | 1997-05-01 | 1998-11-24 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| WO1999025845A1 (en) * | 1997-11-17 | 1999-05-27 | Novo Nordisk Biotech, Inc. | Polypeptides having 5-aminolevulinic acid synthase activity and nucleic acids encoding same |
| KR100511655B1 (ko) * | 1997-12-16 | 2005-08-31 | 노보자임스 에이/에스 | 아미노펩티다제 활성을 갖는 폴리펩티드 및 그것을 코드화하는 핵산 |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
-
1999
- 1999-02-04 US US09/246,178 patent/US6171820B1/en not_active Expired - Lifetime
-
2000
- 2000-02-04 CA CA002325351A patent/CA2325351C/en not_active Expired - Fee Related
- 2000-02-04 WO PCT/US2000/003086 patent/WO2000046344A2/en not_active Ceased
- 2000-02-04 AU AU34839/00A patent/AU3483900A/en not_active Abandoned
- 2000-02-04 JP JP2000597406A patent/JP2003524392A/ja active Pending
-
2005
- 2005-03-18 JP JP2005080273A patent/JP2005245453A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000046344A3 (en) | 2000-12-28 |
| JP2003524392A (ja) | 2003-08-19 |
| AU3483900A (en) | 2000-08-25 |
| WO2000046344A2 (en) | 2000-08-10 |
| CA2325351A1 (en) | 2000-08-10 |
| US6171820B1 (en) | 2001-01-09 |
| JP2005245453A (ja) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2325351C (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| US6479258B1 (en) | Non-stochastic generation of genetic vaccines | |
| US6713279B1 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| US20110165627A1 (en) | Gene site saturation mutagenesis | |
| EP2397549A2 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| US20240263354A1 (en) | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts | |
| US20030219752A1 (en) | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof | |
| CA2320626A1 (en) | Genetic vaccine vector engineering | |
| WO2002092780A2 (en) | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof | |
| US20010006950A1 (en) | Genetic vaccine vector engineering | |
| US20080019988A1 (en) | Targeting of genetic vaccine vectors | |
| US20050164222A1 (en) | Optimization of immunomodulatory properties of genetic vaccines | |
| CA2492661C (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| AU2005201125B2 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| AU2757902A (en) | Genetic vaccine vector engineering | |
| AU2002318140A1 (en) | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof | |
| IL138206A (en) | Methods for non-stochastic generation of progeny polypeptides and hybrid polynucleotides | |
| KR20250060244A (ko) | 조작된 외피보유 벡터 및 이의 사용 방법 | |
| AU2767702A (en) | Targeting of genetic vaccine vectors | |
| HK1236221B (en) | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180205 |